Recent Updates
Recently added Catalysts

Fenofibrate

Phase 2

Non-alcoholic Fatty Liver Disease (NAFLD | Small molecule | Metabolic |AstraZeneca PLC|Last Updated: Sep 25, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment78

FDA Designations

No designations recorded

Clinical trial landscape

Fenofibrate · 1 trial · 2 indications

Phase 2 1
NCT02354976A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.Non-alcoholic Fatty Liver Disease (NAFLD
COMPLETED78 Analytics
PHASE2COMPLETED
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
Non-alcoholic Fatty Liver Disease (NAFLD
NCT0235497678
Unlock trial analytics

Study Endpoints

Primary Endpoints

Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)
Baseline and 12 weeks

To evaluate the efficacy of Epanova compared to placebo with respect to reduction in liver fat content (%) at the end of 12 weeks of double-blinded treatment.

Secondary Endpoints

Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate)
12 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PlaceboPLACEBO_COMPARATOR -
Omega-3 carboxylic acids 4g / dayEXPERIMENTAL -
Fenofibrate 200mgACTIVE_COMPARATOR -

Interventions

NameTypeDescription
PlaceboDRUGPlacebo matching to Omega-3 carboxylic acids (olive oil)
Omega-3 carboxylic acidDRUG4 g administered as 4 x 1 g capsules
Fenofibrate 200mgDRUG200mg capsule administered once daily
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: - Provision of informed consent * Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated venepuncture * Have serum triglycerides ≥1.7 mM * Have liver fat content as assessed by MRI \>5.5% * Have a body mass index (BMI) \>25 and ≤40 kg/m2 , Exclus...

Countries:Sweden
Unlock Eligibility Criteria

Frequently asked questions about Fenofibrate

What is Fenofibrate used for in Non-alcoholic Fatty Liver Disease (NAFLD)?

Fenofibrate is being studied for use in Non-alcoholic Fatty Liver Disease (NAFLD) and hypertriglyceridemia. It is a small molecule in Phase 2 clinical development, evaluated for its effect on liver fat in overweight subjects with these conditions.

What does Fenofibrate target?

Fenofibrate is a small molecule that targets lipid metabolism. It is being investigated for its ability to reduce liver fat in patients with Non-alcoholic Fatty Liver Disease (NAFLD) and hypertriglyceridemia, though the specific molecular target is not detailed.

Who makes Fenofibrate?

Fenofibrate is being developed by AstraZeneca PLC (ticker: AZN). The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating Non-alcoholic Fatty Liver Disease (NAFLD) and hypertriglyceridemia.

What phase is Fenofibrate in?

Fenofibrate is in Phase 2 clinical development. It is an investigational drug, not yet approved, and is being studied for its potential to treat Non-alcoholic Fatty Liver Disease (NAFLD) and hypertriglyceridemia.

What clinical trials is Fenofibrate in?

Fenofibrate has one completed Phase 2 clinical trial, NCT02354976, titled 'A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.' The trial enrolled 78 participants in Sweden and was placebo-controlled.

Is Fenofibrate the same as Epanova?

Fenofibrate is not the same as Epanova. In the clinical trial NCT02354976, Epanova was used as a comparator against fenofibrate to evaluate their effects on liver fat in overweight subjects with Non-alcoholic Fatty Liver Disease (NAFLD) and hypertriglyceridemia.